about
Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisComparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohortTetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical ResearchAminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistancePharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infectionAudiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-upAminoglycosides: activity and resistance.Prevention of adverse events in hospitalized patients using an antimicrobial review program.Global problem of drug-induced hearing loss.Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.Involvement of reactive oxygen species in the action of ciprofloxacin against Escherichia coli.Ototoxicity induced by gentamicin and furosemide.Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Risk factors for toxicity in elderly patients given aminoglycosides once daily.Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.Once-daily aminoglycosides in patients with neutropenic fever.Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis modelOnce-daily aminoglycoside therapy: potential ototoxicity.Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models.An update on otolaryngology in critical care.Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children.Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.Studying outcomes of intensive care unit survivors: the role of the cohort study.Combination therapy for treatment of infections with gram-negative bacteria.The burden of adverse events during treatment of drug-resistant tuberculosis in Namibiad-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant TuberculosisBactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells.The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients.Therapeutic drug monitoring of aminoglycosides in neonates.Polymyxins and analogues bind to ribosomal RNA and interfere with eukaryotic translation in vitro.Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.Once-daily aminoglycoside therapyEmpiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.Aminoglycoside antibiotics: structure, functions and effects on in vitro plant culture and genetic transformation protocols.Antimicrobial therapy for the elderly patient.Allergic Reactions in Hospitalized Patients With a Self-Reported Penicillin Allergy Who Receive a Cephalosporin or Meropenem.Ototoxicity (cochleotoxicity) classifications: A review.Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant TuberculosisOtotoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial.
P2860
Q26829604-1689BB1B-A7BD-4EE2-B890-C7EA6F617D2EQ27318102-E991784E-BD17-4726-8D73-EC36B3638675Q27321070-CA588D48-94A7-4DCD-BD3D-EB658E453FD4Q28138065-59330BC7-68EC-4E85-A5C8-530658D49853Q28328534-740A012B-7ADB-45BD-9736-3931B87E18C4Q30838132-94535F98-AEB9-4963-9753-814DA153D828Q33548221-8831CCBB-4B2D-4540-BD18-DEABCDBA583DQ33772759-2987149F-BAE9-4FCD-B487-EE57594E86E9Q33936855-DAE7CD25-AAA7-4E44-A25B-9C0476E2076CQ34004443-E9B2DC6D-0709-43FE-8270-DC5EE5A7BF29Q34509828-349CF173-F525-4F5A-878B-67D2C379B130Q34521641-646D1F25-CB6D-4AB1-BE8E-744F4AF9D880Q34529303-A8F57A1A-B32F-4580-910D-DAFC7C30045EQ34752229-CFB8C2B2-B67C-40E8-A0B5-88F7A753AB38Q34874579-629F3919-A8D9-4AAB-B840-567B72859E7DQ34985783-373EC0F3-81F8-464A-829B-254E5080EA64Q35109053-01BDF351-FBFE-4853-90A7-129E5430332FQ35127266-3CF1F96D-2BD9-4C4C-9E3A-8E37A289E248Q35693590-3C1DD1C2-5EB9-4CBB-8FF7-83ACAC77A225Q35746986-BC50A4E6-126D-40BB-8D6C-899B39FE7AA3Q35885240-ED797B10-9082-4FCB-8011-36DBD610911BQ35912654-9F7F18A2-4CC8-4431-A230-0C5D0DD33528Q36134894-172EB9AA-0150-4C8E-8B9C-7DC4F506A9EBQ36156077-D8009D04-B8EE-4178-B08B-10A2EF6BFA19Q36317060-79803CEE-06EF-4F98-81BA-D0E800718A5FQ36446781-56A33B72-E4A3-4FDD-824B-136F394B82D9Q37060143-7D82E397-3B78-4389-B971-69D90C5260BCQ37139410-AFCF4737-E248-4394-8942-994477148FD3Q37268122-CC20599D-A06F-4DB1-9796-62DB9A724FC6Q37409465-D0F83CFC-407E-4AFD-8C76-E16AC81C7A33Q37626510-407DEDAA-D6AA-4C7D-9A9D-8917970A002FQ37661512-8B9A4D51-3BA2-4167-BEB3-622A7070DC07Q37730823-70E0D35A-0BB7-4337-BE00-2FE169761F28Q37771799-48101367-5897-43C7-A043-D5786821BFB1Q37774277-A21FC4EA-2489-4F26-AD28-54FBDB01A4E6Q38006505-67015D05-51D8-4D6A-8665-2502E0B9FA1DQ38514140-EBB4DC01-A0A0-4B3B-AC4C-2ABF2165EF09Q38653146-342A13E2-A3C7-4402-97FA-DB1142465193Q39030684-87C88F05-B0C3-4E27-BD4E-722F5B342537Q39510044-3EB13D86-0C9C-42BB-98F6-0403182968FE
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Aminoglycoside-induced hearing loss in humans.
@en
type
label
Aminoglycoside-induced hearing loss in humans.
@en
prefLabel
Aminoglycoside-induced hearing loss in humans.
@en
P2860
P356
P1476
Aminoglycoside-induced hearing loss in humans.
@en
P2093
P2860
P304
P356
10.1128/AAC.33.6.797
P407
P577
1989-06-01T00:00:00Z